Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 290

1.

Role of nucleophosmin in acute myeloid leukemia.

Meani N, Alcalay M.

Expert Rev Anticancer Ther. 2009 Sep;9(9):1283-94. doi: 10.1586/era.09.84. Review.

PMID:
19761432
2.

Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice.

Falini B, Martelli MP, Mecucci C, Liso A, Bolli N, Bigerna B, Pucciarini A, Pileri S, Meloni G, Martelli MF, Haferlach T, Schnittger S.

Haematologica. 2008 May;93(5):775-9. doi: 10.3324/haematol.12225. Epub 2008 Mar 26.

3.

Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias.

Falini B, Nicoletti I, Bolli N, Martelli MP, Liso A, Gorello P, Mandelli F, Mecucci C, Martelli MF.

Haematologica. 2007 Apr;92(4):519-32. Review.

4.

Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: Impact on WHO classification.

Pasqualucci L, Liso A, Martelli MP, Bolli N, Pacini R, Tabarrini A, Carini M, Bigerna B, Pucciarini A, Mannucci R, Nicoletti I, Tiacci E, Meloni G, Specchia G, Cantore N, Di Raimondo F, Pileri S, Mecucci C, Mandelli F, Martelli MF, Falini B.

Blood. 2006 Dec 15;108(13):4146-55. Epub 2006 Aug 22.

5.

Cytoplasmic expression of nucleophosmin accurately predicts mutation in the nucleophosmin gene in patients with acute myeloid leukemia and normal karyotype.

Luo J, Qi C, Xu W, Kamel-Reid S, Brandwein J, Chang H.

Am J Clin Pathol. 2010 Jan;133(1):34-40. doi: 10.1309/AJCPCI1FFE2DRXIV.

PMID:
20023256
6.

Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features.

Falini B, Nicoletti I, Martelli MF, Mecucci C.

Blood. 2007 Feb 1;109(3):874-85. Epub 2006 Sep 28. Review.

7.

Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia.

Falini B, Martelli MP, Bolli N, Bonasso R, Ghia E, Pallotta MT, Diverio D, Nicoletti I, Pacini R, Tabarrini A, Galletti BV, Mannucci R, Roti G, Rosati R, Specchia G, Liso A, Tiacci E, Alcalay M, Luzi L, Volorio S, Bernard L, Guarini A, Amadori S, Mandelli F, Pane F, Lo-Coco F, Saglio G, Pelicci PG, Martelli MF, Mecucci C.

Blood. 2006 Sep 15;108(6):1999-2005. Epub 2006 May 23.

8.

Acute myeloid leukemia with mutated nucleophosmin (NPM1): molecular, pathological, and clinical features.

Falini B.

Cancer Treat Res. 2010;145:149-68. doi: 10.1007/978-0-387-69259-3_9.

PMID:
20306250
9.

Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives.

Falini B, Sportoletti P, Martelli MP.

Curr Opin Oncol. 2009 Nov;21(6):573-81. doi: 10.1097/CCO.0b013e3283313dfa. Review.

PMID:
19770764
10.

Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.

Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, La Starza R, Diverio D, Colombo E, Santucci A, Bigerna B, Pacini R, Pucciarini A, Liso A, Vignetti M, Fazi P, Meani N, Pettirossi V, Saglio G, Mandelli F, Lo-Coco F, Pelicci PG, Martelli MF; GIMEMA Acute Leukemia Working Party.

N Engl J Med. 2005 Jan 20;352(3):254-66. Erratum in: N Engl J Med. 2005 Feb 17;352(7):740.

11.

The leukemia-associated cytoplasmic nucleophosmin mutant is an oncogene with paradoxical functions: Arf inactivation and induction of cellular senescence.

Cheng K, Grisendi S, Clohessy JG, Majid S, Bernardi R, Sportoletti P, Pandolfi PP.

Oncogene. 2007 Nov 22;26(53):7391-400. Epub 2007 Jun 4.

PMID:
17546053
12.

Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance.

Alcalay M, Tiacci E, Bergomas R, Bigerna B, Venturini E, Minardi SP, Meani N, Diverio D, Bernard L, Tizzoni L, Volorio S, Luzi L, Colombo E, Lo Coco F, Mecucci C, Falini B, Pelicci PG.

Blood. 2005 Aug 1;106(3):899-902. Epub 2005 Apr 14.

13.

AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features.

Haferlach C, Mecucci C, Schnittger S, Kohlmann A, Mancini M, Cuneo A, Testoni N, Rege-Cambrin G, Santucci A, Vignetti M, Fazi P, Martelli MP, Haferlach T, Falini B.

Blood. 2009 Oct 1;114(14):3024-32. doi: 10.1182/blood-2009-01-197871. Epub 2009 May 8.

14.

Nucleophosmin mutation in Southeast Asian acute myeloid leukemia: eight novel variants, FLT3 coexistence and prognostic impact of NPM1/FLT3 mutations.

Boonthimat C, Thongnoppakhun W, Auewarakul CU.

Haematologica. 2008 Oct;93(10):1565-9. doi: 10.3324/haematol.12937. Epub 2008 Jul 18.

15.

Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype.

Cazzaniga G, Dell'Oro MG, Mecucci C, Giarin E, Masetti R, Rossi V, Locatelli F, Martelli MF, Basso G, Pession A, Biondi A, Falini B.

Blood. 2005 Aug 15;106(4):1419-22. Epub 2005 May 3.

16.

NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia.

Falini B, Mecucci C, Saglio G, Lo Coco F, Diverio D, Brown P, Pane F, Mancini M, Martelli MP, Pileri S, Haferlach T, Haferlach C, Schnittger S.

Haematologica. 2008 Mar;93(3):439-42. doi: 10.3324/haematol.12153. Epub 2008 Feb 11.

17.

Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-kappaB in AML carrying NPM1 mutations.

Cilloni D, Messa F, Rosso V, Arruga F, Defilippi I, Carturan S, Catalano R, Pautasso M, Panuzzo C, Nicoli P, Messa E, Morotti A, Iacobucci I, Martinelli G, Bracco E, Saglio G.

Leukemia. 2008 Jun;22(6):1234-40. doi: 10.1038/leu.2008.68. Epub 2008 Apr 10. Retraction in: Leukemia. 2010 May;24(5):1103.

PMID:
18401421
18.

Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML.

Falini B, Bolli N, Shan J, Martelli MP, Liso A, Pucciarini A, Bigerna B, Pasqualucci L, Mannucci R, Rosati R, Gorello P, Diverio D, Roti G, Tiacci E, Cazzaniga G, Biondi A, Schnittger S, Haferlach T, Hiddemann W, Martelli MF, Gu W, Mecucci C, Nicoletti I.

Blood. 2006 Jun 1;107(11):4514-23. Epub 2006 Feb 2.

19.

CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice.

Martelli MP, Pettirossi V, Thiede C, Bonifacio E, Mezzasoma F, Cecchini D, Pacini R, Tabarrini A, Ciurnelli R, Gionfriddo I, Manes N, Rossi R, Giunchi L, Oelschl├Ągel U, Brunetti L, Gemei M, Delia M, Specchia G, Liso A, Di Ianni M, Di Raimondo F, Falzetti F, Del Vecchio L, Martelli MF, Falini B.

Blood. 2010 Nov 11;116(19):3907-22. doi: 10.1182/blood-2009-08-238899. Epub 2010 Jul 15.

20.

The incidence and clinical significance of nucleophosmin mutations in childhood AML.

Brown P, McIntyre E, Rau R, Meshinchi S, Lacayo N, Dahl G, Alonzo TA, Chang M, Arceci RJ, Small D.

Blood. 2007 Aug 1;110(3):979-85. Epub 2007 Apr 17.

Supplemental Content

Support Center